Welcome to our dedicated page for Quanterix Corporation news (Ticker: QTRX), a resource for investors and traders seeking the latest updates and insights on Quanterix Corporation stock.
Quanterix Corporation (NASDAQ: QTRX) is a pioneering life sciences company renowned for its groundbreaking ultra-sensitive diagnostic platform. This innovative technology measures individual proteins at concentrations that are up to 1000 times lower than the best immunoassays available today.
At the core of Quanterix's offerings is the Single Molecule Array (Simoa™) technology, which enables the detection and quantification of biomarkers that were previously difficult or impossible to measure. This advancement opens up new applications in various fields, including life sciences research, in-vitro diagnostics, companion diagnostics, and blood screening.
Founded by the esteemed scientist Dr. David Walt, who also co-founded Illumina, Quanterix benefits from a robust intellectual property portfolio initially developed at Tufts University. The company is venture capital-backed and has exclusive licensing rights to this broad IP portfolio.
Quanterix's product lineup is diverse and includes:
- Simoa platform
- Assay Kits
- LDTs & Assay Services
- Simoa p-Tau 217
- Simoa NfL LDT
- Simoa p-Tau 181 LDT
- HD-X Automated Immunoassay Analyzer
- SR-X Biomarker Detection System
- SP-X Imaging and Analysis System
- Simoa Accelerator Laboratory
- Homebrew - Custom Assay Development
- Uman NF-Light
The Simoa bead-based and planar array platforms are designed to detect protein biomarkers in low concentrations in blood, serum, and other fluids, which are undetectable using conventional analog immunoassay technologies.
Quanterix continues to push the boundaries of precision health for life sciences research and diagnostics, tackling significant unmet needs and contributing meaningfully to the scientific community.
Quanterix Corporation (NASDAQ: QTRX) will have its Chairman and CEO, Kevin Hrusovsky, present at the Barclays Global Healthcare Conference on March 15, 2022, at 10:45 a.m. EST. Attendees can register for virtual participation. Hrusovsky will also conduct one-on-one meetings with institutional investors on the same day. A live webcast of his presentation will be available on the Quanterix investor relations website, with replays accessible for 90 days. Quanterix specializes in digitizing biomarker analysis to enhance precision health.
Quanterix Corporation (NASDAQ: QTRX) has announced that its Chairman and CEO, Kevin Hrusovsky, will present at The Cowen 42nd Annual Health Care Conference on March 9, 2022, at 9:50 a.m. EST. Investors can register for a live webcast at the Quanterix investor relations page. Additionally, Hrusovsky will hold virtual meetings with institutional investors on March 8 and 9. Quanterix aims to advance precision health through its Simoa technology to enable early disease detection and better treatment methods.
Quanterix Corporation has entered a collaboration with Eli Lilly to enhance the diagnosis and treatment of Alzheimer’s disease. This partnership includes a non-exclusive license to Lilly’s P-tau217 antibody technology and a commitment of $11 million from Lilly for development this year. The collaboration aims to develop blood-based biomarkers, which could simplify and improve Alzheimer’s diagnostics and treatment monitoring, potentially reducing reliance on invasive procedures. The initiative puts Quanterix in a strong position in Alzheimer’s research and diagnostics.
Quanterix Corporation (NASDAQ: QTRX) announced a leadership transition effective April 25, 2022.
Quanterix Corporation (NASDAQ: QTRX) reported a strong financial performance for the fourth quarter and full year of 2021, achieving a 28% increase in GAAP total revenue, reaching $110.6 million. Notable highlights include a 49% rise in product revenue for Q4, totaling $23.5 million. The company ended the year with approximately $399 million in cash. Key advancements included FDA Breakthrough Device Designation for the pTau-181 blood test for Alzheimer’s disease and successful collaboration agreements with Eli Lilly. A leadership transition is set for April 2022, with Masoud Toloue becoming CEO.
Quanterix Corporation (NASDAQ: QTRX) has received multiple awards in the 2021 Best Places to Work Awards by Comparably, highlighting its commitment to a diverse and inclusive workplace. The company was recognized in five categories: Best Company for Diversity, Best Company for Women, Best Company Culture, Best Company Happiness, and Best Company Compensation. The awards were based on over 1,000 employee ratings. CEO Kevin Hrusovsky emphasized the importance of fostering an environment where all employees feel valued and empowered.
Quanterix Corporation (NASDAQ: QTRX) announced it will release its fourth quarter 2021 financial results on March 1, 2022, prior to market opening. A conference call hosted by CEO Kevin Hrusovsky will take place at 8:30 a.m. EST to discuss the results and provide a business update. Interested parties can participate via phone or listen to a live webcast. Quanterix focuses on digitizing biomarker analysis to enhance precision health, aiming for early disease detection and improved treatments.
Quanterix Corporation (NASDAQ: QTRX) announced that its Chairman and CEO, Kevin Hrusovsky, will present virtually at the SVB Leerink Global Healthcare Conference on February 16 at 4:20 PM EST. A live webcast will be accessible via the company's investor relations website, with on-demand replays available for 90 days post-conference. Hrusovsky will also hold virtual one-on-one meetings with institutional investors on February 18. Quanterix focuses on digitizing biomarker analysis to enhance precision health, with applications in oncology, neurology, and more.
Quanterix Corporation (NASDAQ: QTRX) announced its Simoa® technology is advancing neurodegenerative disease research at the UK Dementia Research Institute's Biomarker Factory. Led by Professor Henrik Zetterberg, this initiative aims to enhance early detection of Alzheimer’s and related diseases through ultrasensitive biomarker testing. The UK DRI is collaborating with Quanterix to develop next-generation Simoa technology, which offers a potential 100x improvement in sensitivity. This progress may lead to earlier diagnosis and more effective treatment options for Alzheimer’s.
Quanterix Corporation (NASDAQ: QTRX) announced that its Simoa® technology has played a significant role in a study published in Science, revealing a strong link between the Epstein-Barr virus (EBV) and multiple sclerosis (MS). The study indicates that EBV infection increases MS risk by 32-fold and correlates with elevated levels of neurofilament light (NfL) protein, suggesting EBV's involvement in nerve damage. This research could enhance early detection and treatment of MS, affecting millions globally.
FAQ
What is the current stock price of Quanterix Corporation (QTRX)?
What is the market cap of Quanterix Corporation (QTRX)?
What is the core technology of Quanterix Corporation?
What are some applications of Quanterix's technology?
Who founded Quanterix Corporation?
What product platforms does Quanterix offer?
What makes Quanterix's diagnostic platform unique?
Is Quanterix publicly traded?
What significant achievements has Quanterix made recently?
What fluids can Quanterix's platforms detect biomarkers in?
Does Quanterix offer custom assay development?
What is the Simoa Accelerator Laboratory?
